Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378427 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2CTSKHPGDGPR119 | |
| SCHEMBL25303284 | 0.85 | MEN1 (0.43) | USP2SMN1; SMN2CTSKHPGDGPR119 | |
| SCHEMBL1973674 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2CTSKHPGDGPR119 | |
| SCHEMBL8101878 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL1118226 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2CTSKHPGDGPR119 | |
| SCHEMBL14242632 | 0.83 | MEN1 (0.43) | USP2SMN1; SMN2CTSKHPGDGPR119 | |
| SCHEMBL6228410 | 0.82 | USP2 (0.55) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL849908 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL16095422 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2CTSKHPGDGPR119 | |
| SCHEMBL23283111 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2CTSKHPGDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-114976225-B | Mixed conductive slurry, preparation method and application thereof | 江苏蓝固新能源科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114976225-A | Mixed conductive slurry, preparation method and application thereof | 江苏蓝固新能源科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-107427699-B | KDM1A inhibitors for the treatment of disease | 伊美格生物科学公司 | 2021-10-19 | — | — | CN | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501773-B2 | 4-fluoro-piperidine T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-1901746-B1 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | USP2 4117/4885SMN1; SMN2 2069/4885CTSK 1540/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | USP2 320/4885SMN1; SMN2 1176/4885CTSK 3803/4885 |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | USP2 320/4885SMN1; SMN2 1176/4885CTSK 3803/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | USP2 320/4885SMN1; SMN2 1176/4885CTSK 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.